

August 25, 1972

Frank S. Caruso, Ph.D.  
Assistant Director  
Clinical Pharmacology  
Bristol Laboratories  
P.O. Box 657  
Syracuse, New York 13201

Dear Dr. Caruso:

While we are anxious to undertake studies of BC-2605a, we are required to obtain additional permission from the Health and Hospital Corporation. There is some delay, which is being dealt with by the College. Until that impediment is dissolved, we cannot begin the planned studies.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:ig